Agfa-Gevaert NV develops, manufactures, and markets various analog and digital systems in Belgium and internationally. The company provides healthcare's enterprise imaging platform. It also offers printers, inks, and software for sign and display and packaging printing companies; inkjet inks and fluids for various industrial inkjet applications, such as signs, displays, billboards, promotional materials, packaging, leather goods, laminated flooring, and decorative materials, as well as for printed electronics industry; electrolysis membranes to the hydrogen production industry; and printable synthetic papers and films for graphics, non-destructive testing, aerial photography, and printed circuit board production. In addition, it provides analog and digital imaging technology for diagnostic imaging market to meet the needs of specialized clinicians in hospitals and imaging centers; and X-ray film, hardcopy film and printers, digital radiography equipment, and image processing software. Further, it offers SmartXR that provides radiographers with predictive workflow assistance which includes digital radiography tools for dose, alignment, patient positioning, image rotation, and others. Additionally, the company engages in supply of film and chemicals, as well support services. It sells its products through its own sales organization, as well as through a network of agents and representatives. Agfa-Gevaert NV was founded in 1867 and is headquartered in Mortsel, Belgium.…
Vallourec sees Q4 EBITDA below expectations as Middle East disruption hits margins
Agfa-Gevaert (EBR: AGFB) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Specialty Industrial Machinery industry, part of the Industrials sector, and reports about 4,211 employees.
The shares were at 0.3285 EUR on 20 November 2026, down 48.1% over 52 weeks. Its 52-week range is 0.3005 EUR to 0.6450 EUR: the price is 49.1% below the high and 9.3% above the low.
Its market capitalisation is 50.86M EUR.
Agfa-Gevaert reports return on equity of -28.0%, an operating margin of -4.2% and revenue down 18.3% year over year.
Its debt exceeds its cash by 130.00M EUR, a debt-to-equity ratio of 0.67. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Underperform; their mean price target of 0.5000 EUR is 52.2% above the current price. The next earnings report is expected on 10 March 2027.